Avaxia Biologics develops orally-delivered antibody therapeutics using a proprietary antibody platform.
Avaxia Biologics is a private, early-stage company developing orally-delivered antibody therapeutics using a proprietary antibody platform. The company is pursuing products for oral mucositis, inflammatory bowel disease, and diabetes, and obesity.Avaxia Biologics was founded in 2005 and headquartered in Lexington, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 7, 2013 | Series B | $11.50M | 2 | — | — | Detail |
Dec 19, 2012 | Series B | $6.40M | 3 | — | — | Detail |
Feb 14, 2012 | Series A | $4.10M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Granite State Angels | — | Series B |
North Country Angels | — | Series B |
Keiretsu Forum | — | Series B |